Becton, Dickinson and Company (BDX)
NYSE: BDX · Real-Time Price · USD
167.95
+0.81 (0.48%)
At close: May 8, 2025, 4:00 PM
169.00
+1.05 (0.63%)
Pre-market: May 9, 2025, 8:42 AM EDT
BDX Revenue
Becton, Dickinson and Company had revenue of $5.27B in the quarter ending March 31, 2025, with 4.50% growth. This brings the company's revenue in the last twelve months to $20.87B, up 5.84% year-over-year. In the fiscal year ending September 30, 2024, Becton, Dickinson and Company had annual revenue of $20.18B with 4.16% growth.
Revenue (ttm)
$20.87B
Revenue Growth
+5.84%
P/S Ratio
2.33
Revenue / Employee
$285,849
Employees
73,000
Market Cap
48.14B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 20.18B | 806.00M | 4.16% |
| Sep 30, 2023 | 19.37B | 502.00M | 2.66% |
| Sep 30, 2022 | 18.87B | -261.00M | -1.36% |
| Sep 30, 2021 | 19.13B | 3.06B | 19.02% |
| Sep 30, 2020 | 16.07B | -1.22B | -7.03% |
| Sep 30, 2019 | Pro | Pro | Pro |
| Sep 30, 2018 | Pro | Pro | Pro |
| Sep 30, 2017 | Pro | Pro | Pro |
| Sep 30, 2016 | Pro | Pro | Pro |
| Sep 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Thermo Fisher Scientific | 42.90B |
BDX News
- 22 hours ago - The Best Health Care Stocks to Buy - Kiplinger
- 2 days ago - Buy 3 "Safer" Dividend Kings Of 25 From May's 55 - Seeking Alpha
- 6 days ago - Becton Dickinson Vitals Drop: Analysts 'Have Been Wrong' On This Med Tech Stock For Years - Benzinga
- 6 days ago - Stock Of The Day – Bullish Capitulation In Becton, Dickinson? - Benzinga
- 7 days ago - 9 Dividend Aristocrats Potentially Set To Soar, No Matter What Happens Next - Seeking Alpha
- 7 days ago - Medical-products maker Becton Dickinson says cuts in global research funding have hurt sales - Market Watch
- 7 days ago - Becton, Dickinson and Company (BDX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Potential Tariff Bites Into Becton Dickinson 2025 Profit Outlook, Company Will Invest $2.5 Billion To Boost US Manufacturing - Benzinga